686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
_version_ | 1818562683737210880 |
---|---|
author | Tao Huang An Song Ryan Stafford Maria Jose Costa Zhiqiang Ku Jing-Tyan Ma Krista McCutcheon Xiaoye Liu Heyu Chen Kyu Hong Ningyan Zhang Zhiqiang An Cheng Cheng Zhang X Charlene Liao |
author_facet | Tao Huang An Song Ryan Stafford Maria Jose Costa Zhiqiang Ku Jing-Tyan Ma Krista McCutcheon Xiaoye Liu Heyu Chen Kyu Hong Ningyan Zhang Zhiqiang An Cheng Cheng Zhang X Charlene Liao |
author_sort | Tao Huang |
collection | DOAJ |
first_indexed | 2024-12-14T01:06:59Z |
format | Article |
id | doaj.art-bb1d0a2138c845c9b062f11fd56be607 |
institution | Directory Open Access Journal |
issn | 2051-1426 |
language | English |
last_indexed | 2024-12-14T01:06:59Z |
publishDate | 2020-11-01 |
publisher | BMJ Publishing Group |
record_format | Article |
series | Journal for ImmunoTherapy of Cancer |
spelling | doaj.art-bb1d0a2138c845c9b062f11fd56be6072022-12-21T23:22:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0686686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2Tao Huang0An Song1Ryan Stafford2Maria Jose Costa3Zhiqiang Ku4Jing-Tyan Ma5Krista McCutcheon6Xiaoye Liu7Heyu Chen8Kyu Hong9Ningyan Zhang10Zhiqiang An11Cheng Cheng Zhang12X Charlene Liao131Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA2University of Texas Health Science Center, Houston, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA3University of Texas Southwestern, Dallas, TX, USA3University of Texas Southwestern, Dallas, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA2University of Texas Health Science Center, Houston, TX, USA2University of Texas Health Science Center, Houston, TX, USA3University of Texas Southwestern, Dallas, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA |
spellingShingle | Tao Huang An Song Ryan Stafford Maria Jose Costa Zhiqiang Ku Jing-Tyan Ma Krista McCutcheon Xiaoye Liu Heyu Chen Kyu Hong Ningyan Zhang Zhiqiang An Cheng Cheng Zhang X Charlene Liao 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 Journal for ImmunoTherapy of Cancer |
title | 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 |
title_full | 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 |
title_fullStr | 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 |
title_full_unstemmed | 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 |
title_short | 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2 |
title_sort | 686 preclinical characterization of a novel therapeutic antibody targeting lilrb2 |
work_keys_str_mv | AT taohuang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT ansong 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT ryanstafford 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT mariajosecosta 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT zhiqiangku 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT jingtyanma 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT kristamccutcheon 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT xiaoyeliu 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT heyuchen 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT kyuhong 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT ningyanzhang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT zhiqiangan 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT chengchengzhang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 AT xcharleneliao 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2 |